These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33800852)

  • 1. Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.
    Menendez JA; Papadimitropoulou A; Vander Steen T; Cuyàs E; Oza-Gajera BP; Verdura S; Espinoza I; Vellon L; Mehmi I; Lupu R
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
    Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
    Lupu R; Menendez JA
    Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
    Yan C; Wei H; Minjuan Z; Yan X; Jingyue Y; Wenchao L; Sheng H
    PLoS One; 2014; 9(5):e97697. PubMed ID: 24866893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
    Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
    Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
    Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
    Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
    Gruslova A; McClellan B; Balinda HU; Viswanadhapalli S; Alers V; Sareddy GR; Huang T; Garcia M; deGraffenried L; Vadlamudi RK; Brenner AJ
    Breast Cancer Res Treat; 2021 Jun; 187(2):375-386. PubMed ID: 33893909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
    Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
    Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.
    Menendez JA; Vellon L; Espinoza I; Lupu R
    Oncoscience; 2016; 3(7-8):242-257. PubMed ID: 27713913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
    BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
    Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.
    Zhang Y; Leonard M; Shu Y; Yang Y; Shu D; Guo P; Zhang X
    ACS Nano; 2017 Jan; 11(1):335-346. PubMed ID: 27966906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
    Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
    Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells.
    Menendez JA; Lupu R
    Oncogenesis; 2017 Feb; 6(2):e299. PubMed ID: 28240737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.